Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration.
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has announced an antibody discovery, option, and license agreement with Bayer, potentially worth up to $188M. Bayer will have the option to license antibodies discovered under the collaboration.
October 05, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's agreement with Bayer could potentially bring in up to $188M, which could positively impact the company's financials and stock price.
The agreement with Bayer could potentially bring significant revenue to Twist Bioscience, which could improve the company's financials and increase investor confidence, potentially leading to a rise in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100